 William Robinson
Concepts (847)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 93 | 2024 | 724 | 7.250 |
Why?
| | Skin Neoplasms | 48 | 2024 | 820 | 3.950 |
Why?
| | Proto-Oncogene Proteins c-kit | 6 | 2019 | 68 | 1.740 |
Why?
| | Mastocytosis | 3 | 2021 | 11 | 1.500 |
Why?
| | Antineoplastic Agents | 19 | 2024 | 2042 | 1.180 |
Why?
| | Spinal Fusion | 4 | 2022 | 230 | 0.970 |
Why?
| | Melanocytes | 7 | 2024 | 63 | 0.900 |
Why?
| | Mutation | 17 | 2022 | 3696 | 0.820 |
Why?
| | Antibodies, Monoclonal | 7 | 2018 | 1357 | 0.800 |
Why?
| | Vitiligo | 5 | 2024 | 41 | 0.780 |
Why?
| | Osteoporotic Fractures | 2 | 2020 | 57 | 0.770 |
Why?
| | Thoracic Vertebrae | 2 | 2020 | 74 | 0.770 |
Why?
| | Mucous Membrane | 2 | 2024 | 121 | 0.740 |
Why?
| | Mastocytosis, Cutaneous | 1 | 2021 | 5 | 0.720 |
Why?
| | Piperazines | 7 | 2018 | 333 | 0.700 |
Why?
| | Middle Aged | 94 | 2024 | 30921 | 0.680 |
Why?
| | Gastrointestinal Stromal Tumors | 2 | 2019 | 46 | 0.670 |
Why?
| | Germ-Line Mutation | 2 | 2019 | 138 | 0.630 |
Why?
| | Humans | 209 | 2024 | 128495 | 0.630 |
Why?
| | Oncogene Proteins, Fusion | 2 | 2018 | 200 | 0.630 |
Why?
| | Exome | 2 | 2017 | 220 | 0.630 |
Why?
| | Spinal Fractures | 1 | 2020 | 81 | 0.620 |
Why?
| | Esophageal Achalasia | 1 | 2019 | 28 | 0.610 |
Why?
| | Intervertebral Disc Displacement | 1 | 2019 | 39 | 0.600 |
Why?
| | Histiocytosis, Sinus | 1 | 2018 | 7 | 0.590 |
Why?
| | Neurofibromin 1 | 2 | 2017 | 25 | 0.590 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 5 | 2013 | 69 | 0.590 |
Why?
| | Humeral Head | 1 | 2017 | 13 | 0.580 |
Why?
| | Osteoporosis | 2 | 2020 | 233 | 0.580 |
Why?
| | Orthopedics | 1 | 2020 | 135 | 0.570 |
Why?
| | Arthroplasty, Replacement, Shoulder | 1 | 2017 | 23 | 0.570 |
Why?
| | Carcinoma, Merkel Cell | 2 | 2008 | 18 | 0.560 |
Why?
| | Skin Pigmentation | 4 | 2024 | 45 | 0.550 |
Why?
| | Intention | 1 | 2019 | 162 | 0.550 |
Why?
| | Genetic Predisposition to Disease | 5 | 2019 | 2269 | 0.550 |
Why?
| | Myeloid-Derived Suppressor Cells | 3 | 2024 | 62 | 0.540 |
Why?
| | Female | 118 | 2024 | 68266 | 0.540 |
Why?
| | RNA Splicing Factors | 1 | 2017 | 52 | 0.540 |
Why?
| | Databases, Factual | 4 | 2020 | 1267 | 0.540 |
Why?
| | Proto-Oncogene Proteins B-raf | 6 | 2020 | 212 | 0.530 |
Why?
| | Granulocytes | 26 | 1988 | 79 | 0.530 |
Why?
| | Hematopoiesis | 24 | 1988 | 185 | 0.530 |
Why?
| | Forecasting | 2 | 2017 | 356 | 0.510 |
Why?
| | MicroRNAs | 4 | 2023 | 674 | 0.510 |
Why?
| | Shoulder Joint | 1 | 2017 | 163 | 0.500 |
Why?
| | Ultraviolet Therapy | 4 | 2024 | 16 | 0.500 |
Why?
| | Osteoarthritis | 1 | 2017 | 166 | 0.490 |
Why?
| | Sentinel Lymph Node Biopsy | 7 | 2021 | 107 | 0.490 |
Why?
| | Adult | 94 | 2024 | 35299 | 0.490 |
Why?
| | Biomarkers, Tumor | 8 | 2019 | 1179 | 0.480 |
Why?
| | Aged | 63 | 2024 | 21974 | 0.480 |
Why?
| | Male | 100 | 2024 | 63043 | 0.470 |
Why?
| | Neoplasms, Second Primary | 3 | 2023 | 106 | 0.470 |
Why?
| | Phosphoproteins | 1 | 2017 | 329 | 0.470 |
Why?
| | Pyrimidines | 4 | 2008 | 449 | 0.460 |
Why?
| | Aged, 80 and over | 21 | 2021 | 7057 | 0.460 |
Why?
| | Cell Line, Tumor | 18 | 2024 | 3178 | 0.440 |
Why?
| | Colony-Stimulating Factors | 20 | 1988 | 35 | 0.440 |
Why?
| | Microphthalmia-Associated Transcription Factor | 3 | 2008 | 14 | 0.430 |
Why?
| | Nevus | 3 | 2010 | 24 | 0.420 |
Why?
| | Milk, Human | 1 | 2014 | 149 | 0.400 |
Why?
| | Neoplastic Stem Cells | 5 | 2018 | 380 | 0.390 |
Why?
| | Military Personnel | 1 | 2019 | 514 | 0.390 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2012 | 30 | 0.380 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 11 | 2023 | 1562 | 0.370 |
Why?
| | Pyrroles | 3 | 2021 | 190 | 0.370 |
Why?
| | Breast Neoplasms | 8 | 2017 | 2135 | 0.360 |
Why?
| | Triazines | 2 | 2021 | 38 | 0.360 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 3 | 2024 | 40 | 0.360 |
Why?
| | Gene Expression Regulation, Neoplastic | 6 | 2018 | 1349 | 0.350 |
Why?
| | Sulfonamides | 4 | 2020 | 495 | 0.350 |
Why?
| | Gastrointestinal Neoplasms | 2 | 2008 | 72 | 0.340 |
Why?
| | Lymph Node Excision | 5 | 2021 | 164 | 0.340 |
Why?
| | Lymphatic Metastasis | 7 | 2013 | 317 | 0.340 |
Why?
| | Sentinel Lymph Node | 2 | 2021 | 42 | 0.340 |
Why?
| | Adenocarcinoma | 5 | 2016 | 894 | 0.330 |
Why?
| | Genes, p16 | 3 | 2007 | 19 | 0.330 |
Why?
| | Lumbar Vertebrae | 3 | 2022 | 231 | 0.320 |
Why?
| | High-Throughput Nucleotide Sequencing | 3 | 2018 | 487 | 0.310 |
Why?
| | RNA, Neoplasm | 2 | 2008 | 87 | 0.310 |
Why?
| | Treatment Outcome | 15 | 2022 | 10162 | 0.310 |
Why?
| | Leukocytes | 14 | 1986 | 303 | 0.310 |
Why?
| | Immunohistochemistry | 6 | 2019 | 1668 | 0.300 |
Why?
| | Lumbosacral Region | 2 | 2019 | 56 | 0.300 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2022 | 177 | 0.300 |
Why?
| | Sarcoma, Clear Cell | 1 | 2008 | 8 | 0.300 |
Why?
| | Lymphoma, Mantle-Cell | 1 | 2008 | 19 | 0.300 |
Why?
| | Quality Improvement | 2 | 2018 | 1097 | 0.300 |
Why?
| | Tumor Suppressor Proteins | 4 | 2024 | 313 | 0.300 |
Why?
| | Cyclins | 1 | 2008 | 85 | 0.290 |
Why?
| | Pyrazoles | 2 | 2021 | 404 | 0.290 |
Why?
| | Nitrophenols | 3 | 2017 | 33 | 0.290 |
Why?
| | Proto-Oncogene Proteins | 3 | 2018 | 633 | 0.280 |
Why?
| | Tretinoin | 4 | 2023 | 127 | 0.280 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 1 | 2008 | 45 | 0.280 |
Why?
| | Biphenyl Compounds | 3 | 2017 | 60 | 0.280 |
Why?
| | Prognosis | 14 | 2024 | 3780 | 0.270 |
Why?
| | Tamoxifen | 3 | 2016 | 200 | 0.270 |
Why?
| | Cell Transformation, Neoplastic | 3 | 2018 | 325 | 0.270 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2007 | 38 | 0.260 |
Why?
| | GTP Phosphohydrolases | 4 | 2020 | 84 | 0.260 |
Why?
| | Arthroplasty, Replacement, Knee | 2 | 2022 | 301 | 0.260 |
Why?
| | Interferon-alpha | 6 | 2006 | 193 | 0.250 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 5 | 2021 | 229 | 0.250 |
Why?
| | Hair Color | 2 | 2024 | 16 | 0.240 |
Why?
| | Xenograft Model Antitumor Assays | 6 | 2018 | 812 | 0.240 |
Why?
| | Follow-Up Studies | 12 | 2020 | 4874 | 0.240 |
Why?
| | DNA, Neoplasm | 5 | 2017 | 159 | 0.240 |
Why?
| | Liposarcoma | 1 | 2005 | 27 | 0.240 |
Why?
| | Epidermis | 2 | 2024 | 154 | 0.240 |
Why?
| | T-Lymphocytes, Regulatory | 3 | 2023 | 366 | 0.230 |
Why?
| | Intestinal Neoplasms | 1 | 2024 | 28 | 0.230 |
Why?
| | Intestine, Small | 2 | 2024 | 145 | 0.230 |
Why?
| | Polymerase Chain Reaction | 6 | 2008 | 1027 | 0.230 |
Why?
| | Ultraviolet Rays | 4 | 2024 | 380 | 0.220 |
Why?
| | Mice | 28 | 2024 | 16620 | 0.220 |
Why?
| | Dasatinib | 1 | 2024 | 51 | 0.220 |
Why?
| | Burns | 7 | 1997 | 284 | 0.220 |
Why?
| | Hyperpigmentation | 1 | 2024 | 25 | 0.220 |
Why?
| | Lymph Nodes | 1 | 2006 | 466 | 0.220 |
Why?
| | Piperidines | 2 | 2018 | 191 | 0.220 |
Why?
| | Genomics | 4 | 2024 | 715 | 0.220 |
Why?
| | Melatonin | 3 | 1994 | 124 | 0.220 |
Why?
| | Neoplasm Staging | 10 | 2019 | 1292 | 0.220 |
Why?
| | Dacarbazine | 7 | 2012 | 94 | 0.220 |
Why?
| | Hair Follicle | 3 | 2020 | 43 | 0.210 |
Why?
| | Mice, Nude | 4 | 2020 | 678 | 0.210 |
Why?
| | Exons | 3 | 2019 | 339 | 0.210 |
Why?
| | Stem Cells | 4 | 2017 | 578 | 0.210 |
Why?
| | Flavonoids | 1 | 2003 | 78 | 0.210 |
Why?
| | Drug Resistance, Neoplasm | 6 | 2016 | 749 | 0.210 |
Why?
| | HLA-DR Antigens | 2 | 2022 | 224 | 0.210 |
Why?
| | Genes, erbB-1 | 2 | 2016 | 17 | 0.200 |
Why?
| | Lysophospholipids | 1 | 2023 | 68 | 0.200 |
Why?
| | Chromosome Aberrations | 2 | 1994 | 149 | 0.200 |
Why?
| | Pedigree | 3 | 2024 | 485 | 0.200 |
Why?
| | Molecular Targeted Therapy | 3 | 2024 | 385 | 0.200 |
Why?
| | Cervical Vertebrae | 2 | 2021 | 132 | 0.200 |
Why?
| | Hematopoietic Stem Cells | 11 | 1986 | 379 | 0.200 |
Why?
| | Colonic Neoplasms | 1 | 2024 | 243 | 0.190 |
Why?
| | Registries | 3 | 2020 | 1883 | 0.190 |
Why?
| | Lordosis | 1 | 2022 | 14 | 0.190 |
Why?
| | Neoplasm Recurrence, Local | 9 | 2016 | 958 | 0.190 |
Why?
| | Spondylolisthesis | 1 | 2021 | 8 | 0.190 |
Why?
| | Mastocytosis, Systemic | 1 | 2021 | 8 | 0.190 |
Why?
| | Clone Cells | 7 | 2010 | 256 | 0.190 |
Why?
| | Retrospective Studies | 16 | 2022 | 14471 | 0.190 |
Why?
| | Spinal Cord Diseases | 1 | 2021 | 41 | 0.190 |
Why?
| | Cell Cycle Proteins | 3 | 2007 | 581 | 0.180 |
Why?
| | Risk Factors | 8 | 2020 | 9737 | 0.180 |
Why?
| | Animals | 34 | 2024 | 34647 | 0.180 |
Why?
| | Gene Expression Profiling | 5 | 2024 | 1689 | 0.180 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2024 | 842 | 0.170 |
Why?
| | Interleukin-1 | 2 | 2019 | 954 | 0.170 |
Why?
| | Drug Therapy, Combination | 5 | 2016 | 1016 | 0.170 |
Why?
| | Sonication | 1 | 2020 | 13 | 0.170 |
Why?
| | Leukemia | 8 | 1988 | 228 | 0.170 |
Why?
| | Turner Syndrome | 1 | 2001 | 52 | 0.170 |
Why?
| | Adult Stem Cells | 1 | 2020 | 38 | 0.170 |
Why?
| | Laser Capture Microdissection | 2 | 2017 | 22 | 0.170 |
Why?
| | Transcription, Genetic | 5 | 2017 | 1404 | 0.170 |
Why?
| | Tissue Culture Techniques | 1 | 2020 | 68 | 0.170 |
Why?
| | Arthroplasty, Replacement, Finger | 1 | 2019 | 2 | 0.160 |
Why?
| | Aniline Compounds | 1 | 2020 | 96 | 0.160 |
Why?
| | beta Catenin | 2 | 2020 | 218 | 0.160 |
Why?
| | Finger Joint | 1 | 2019 | 8 | 0.160 |
Why?
| | Tumor Cells, Cultured | 6 | 2003 | 930 | 0.160 |
Why?
| | Finger Phalanges | 1 | 2019 | 9 | 0.160 |
Why?
| | Prosthesis-Related Infections | 1 | 2020 | 73 | 0.160 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2019 | 76 | 0.160 |
Why?
| | Sequence Analysis, RNA | 3 | 2018 | 428 | 0.160 |
Why?
| | Nomograms | 1 | 2019 | 47 | 0.160 |
Why?
| | Heart Neoplasms | 2 | 1999 | 49 | 0.160 |
Why?
| | RNA | 2 | 2016 | 881 | 0.160 |
Why?
| | Bone Density | 2 | 2020 | 474 | 0.160 |
Why?
| | Prostheses and Implants | 1 | 2020 | 132 | 0.160 |
Why?
| | Visual Analog Scale | 1 | 2019 | 28 | 0.160 |
Why?
| | Signal Transduction | 7 | 2023 | 4825 | 0.150 |
Why?
| | Reoperation | 2 | 2019 | 544 | 0.150 |
Why?
| | c-Mer Tyrosine Kinase | 1 | 2018 | 44 | 0.150 |
Why?
| | CDC2 Protein Kinase | 1 | 2018 | 31 | 0.150 |
Why?
| | Intervertebral Disc Degeneration | 1 | 2019 | 33 | 0.150 |
Why?
| | Ipilimumab | 1 | 2018 | 31 | 0.150 |
Why?
| | Case-Control Studies | 5 | 2022 | 3339 | 0.150 |
Why?
| | SOXB1 Transcription Factors | 1 | 2018 | 57 | 0.150 |
Why?
| | Hospital Costs | 1 | 2018 | 114 | 0.150 |
Why?
| | Septins | 1 | 2018 | 43 | 0.150 |
Why?
| | Leukemia, Myeloid | 10 | 1984 | 45 | 0.140 |
Why?
| | Zinc Finger Protein GLI1 | 1 | 2017 | 23 | 0.140 |
Why?
| | Bone Marrow Cells | 17 | 1983 | 293 | 0.140 |
Why?
| | Imatinib Mesylate | 2 | 2008 | 67 | 0.140 |
Why?
| | Biofilms | 1 | 2020 | 243 | 0.140 |
Why?
| | Receptors, Androgen | 1 | 1998 | 143 | 0.140 |
Why?
| | Colony-Forming Units Assay | 19 | 1988 | 90 | 0.140 |
Why?
| | Burns, Electric | 3 | 1986 | 26 | 0.140 |
Why?
| | Low Back Pain | 1 | 2019 | 102 | 0.140 |
Why?
| | Bone Marrow | 14 | 1983 | 267 | 0.140 |
Why?
| | Microtubule-Associated Proteins | 1 | 2018 | 189 | 0.140 |
Why?
| | Secondary Prevention | 1 | 2018 | 219 | 0.140 |
Why?
| | Cisplatin | 4 | 2006 | 298 | 0.130 |
Why?
| | Databases, Genetic | 1 | 2018 | 229 | 0.130 |
Why?
| | Benzamides | 2 | 2008 | 195 | 0.130 |
Why?
| | Membrane Proteins | 4 | 2020 | 1109 | 0.130 |
Why?
| | Cancer-Associated Fibroblasts | 1 | 2016 | 13 | 0.130 |
Why?
| | Adenine | 1 | 2018 | 256 | 0.130 |
Why?
| | Freezing | 4 | 2014 | 86 | 0.130 |
Why?
| | Preservation, Biological | 3 | 2014 | 7 | 0.130 |
Why?
| | Pain Measurement | 1 | 2019 | 488 | 0.130 |
Why?
| | Bone Marrow Transplantation | 10 | 1986 | 269 | 0.130 |
Why?
| | Carrier Proteins | 2 | 2000 | 732 | 0.130 |
Why?
| | Genes, Tumor Suppressor | 1 | 1996 | 86 | 0.130 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 1994 | 112 | 0.130 |
Why?
| | Adolescent | 34 | 2020 | 20304 | 0.130 |
Why?
| | Mitochondrial Proteins | 1 | 2018 | 245 | 0.130 |
Why?
| | Lung Neoplasms | 7 | 2016 | 2329 | 0.130 |
Why?
| | Drug Synergism | 4 | 2018 | 357 | 0.130 |
Why?
| | Apoptosis | 4 | 2018 | 2437 | 0.130 |
Why?
| | Protein Isoforms | 1 | 2017 | 378 | 0.130 |
Why?
| | Brain Neoplasms | 4 | 1994 | 1172 | 0.130 |
Why?
| | Interferon Type I | 4 | 1994 | 140 | 0.130 |
Why?
| | Lentigo | 1 | 2015 | 6 | 0.120 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1200 | 0.120 |
Why?
| | Cell Cycle | 3 | 2010 | 581 | 0.120 |
Why?
| | Aldehyde Dehydrogenase | 2 | 2014 | 101 | 0.120 |
Why?
| | Antigens, Neoplasm | 5 | 2005 | 308 | 0.120 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 5 | 2011 | 941 | 0.120 |
Why?
| | Radiography | 1 | 2017 | 795 | 0.120 |
Why?
| | Neoplastic Cells, Circulating | 2 | 2006 | 71 | 0.120 |
Why?
| | Head and Neck Neoplasms | 3 | 2013 | 533 | 0.120 |
Why?
| | Lymphoma | 4 | 1991 | 195 | 0.120 |
Why?
| | Leukocyte Count | 20 | 1988 | 326 | 0.120 |
Why?
| | Myeloproliferative Disorders | 1 | 1995 | 26 | 0.120 |
Why?
| | Oligopeptides | 1 | 2016 | 255 | 0.120 |
Why?
| | Fenretinide | 1 | 2014 | 7 | 0.120 |
Why?
| | Desiccation | 1 | 2014 | 20 | 0.120 |
Why?
| | Survival Analysis | 6 | 2010 | 1265 | 0.120 |
Why?
| | Cell Division | 11 | 1998 | 777 | 0.120 |
Why?
| | Cell Survival | 8 | 2018 | 1076 | 0.110 |
Why?
| | Peptides | 2 | 2008 | 915 | 0.110 |
Why?
| | Survival Rate | 8 | 2024 | 1871 | 0.110 |
Why?
| | Peptide Fragments | 1 | 2018 | 688 | 0.110 |
Why?
| | Cohort Studies | 3 | 2024 | 5402 | 0.110 |
Why?
| | Perineum | 1 | 1993 | 26 | 0.110 |
Why?
| | Receptors, Estrogen | 1 | 2016 | 425 | 0.110 |
Why?
| | Internet | 1 | 2018 | 613 | 0.110 |
Why?
| | Basigin | 1 | 2013 | 25 | 0.110 |
Why?
| | Ear, External | 1 | 2013 | 24 | 0.110 |
Why?
| | Dose-Response Relationship, Drug | 7 | 2021 | 1951 | 0.100 |
Why?
| | Mohs Surgery | 1 | 2013 | 25 | 0.100 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2013 | 117 | 0.100 |
Why?
| | Extracellular Space | 1 | 2013 | 119 | 0.100 |
Why?
| | Cell Proliferation | 5 | 2018 | 2345 | 0.100 |
Why?
| | Sweat Gland Neoplasms | 1 | 2012 | 5 | 0.100 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 1992 | 54 | 0.100 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 1992 | 56 | 0.100 |
Why?
| | In Situ Hybridization, Fluorescence | 2 | 2017 | 313 | 0.100 |
Why?
| | Alcohol Oxidoreductases | 1 | 2013 | 48 | 0.100 |
Why?
| | BRCA1 Protein | 1 | 2013 | 65 | 0.100 |
Why?
| | Alleles | 2 | 2022 | 842 | 0.100 |
Why?
| | Side-Population Cells | 1 | 2012 | 8 | 0.100 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2013 | 154 | 0.100 |
Why?
| | Vitamins | 1 | 1994 | 174 | 0.100 |
Why?
| | Decision Making | 1 | 2019 | 847 | 0.100 |
Why?
| | Bone Marrow Diseases | 3 | 1983 | 19 | 0.100 |
Why?
| | Child | 16 | 2020 | 20805 | 0.100 |
Why?
| | Ricin | 1 | 1991 | 8 | 0.100 |
Why?
| | Escherichia coli Infections | 4 | 1981 | 112 | 0.100 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2013 | 622 | 0.100 |
Why?
| | Sequence Analysis, DNA | 2 | 2005 | 775 | 0.100 |
Why?
| | Peer Review | 1 | 2012 | 47 | 0.090 |
Why?
| | Severity of Illness Index | 2 | 2018 | 2719 | 0.090 |
Why?
| | Malpractice | 1 | 2012 | 38 | 0.090 |
Why?
| | Immunotoxins | 1 | 1991 | 54 | 0.090 |
Why?
| | Phenotype | 5 | 2024 | 3051 | 0.090 |
Why?
| | DNA Mutational Analysis | 2 | 2016 | 385 | 0.090 |
Why?
| | Complement C1q | 1 | 2011 | 37 | 0.090 |
Why?
| | United States | 3 | 2020 | 13840 | 0.090 |
Why?
| | History, 21st Century | 1 | 2012 | 180 | 0.090 |
Why?
| | Cyclosporine | 1 | 1991 | 171 | 0.090 |
Why?
| | Keratinocytes | 2 | 2024 | 237 | 0.090 |
Why?
| | Immune Tolerance | 2 | 1991 | 350 | 0.090 |
Why?
| | Agranulocytosis | 6 | 1986 | 30 | 0.090 |
Why?
| | History, 20th Century | 1 | 2012 | 288 | 0.090 |
Why?
| | Neoplasms | 5 | 2018 | 2463 | 0.090 |
Why?
| | Pancreatitis | 1 | 1991 | 128 | 0.090 |
Why?
| | Predictive Value of Tests | 2 | 2006 | 1938 | 0.090 |
Why?
| | Time Factors | 15 | 2019 | 6505 | 0.090 |
Why?
| | Blast Crisis | 1 | 1990 | 33 | 0.090 |
Why?
| | Risk Assessment | 1 | 2019 | 3232 | 0.080 |
Why?
| | Urinary Bladder Neoplasms | 2 | 1983 | 226 | 0.080 |
Why?
| | Bacterial Infections | 4 | 1989 | 235 | 0.080 |
Why?
| | Vitamin E | 2 | 1994 | 120 | 0.080 |
Why?
| | Disease-Free Survival | 5 | 2019 | 647 | 0.080 |
Why?
| | Glycoproteins | 5 | 1977 | 337 | 0.080 |
Why?
| | Tomography, X-Ray Computed | 2 | 2018 | 2517 | 0.080 |
Why?
| | Cells, Cultured | 12 | 2019 | 4017 | 0.080 |
Why?
| | Indium Radioisotopes | 1 | 1989 | 13 | 0.080 |
Why?
| | Recombinant Proteins | 7 | 1994 | 1291 | 0.080 |
Why?
| | Interleukin-6 | 1 | 2013 | 715 | 0.080 |
Why?
| | Transforming Growth Factor beta | 3 | 2019 | 443 | 0.080 |
Why?
| | Cell Differentiation | 7 | 2015 | 1900 | 0.080 |
Why?
| | Osteonecrosis | 2 | 1986 | 22 | 0.080 |
Why?
| | Neutrophils | 8 | 1988 | 1192 | 0.080 |
Why?
| | Lithium | 5 | 1986 | 37 | 0.080 |
Why?
| | Inflammation | 1 | 2019 | 2666 | 0.080 |
Why?
| | Cyclin D | 1 | 2008 | 8 | 0.080 |
Why?
| | Patient Safety | 1 | 2012 | 286 | 0.080 |
Why?
| | Lymphocytes | 7 | 2006 | 368 | 0.080 |
Why?
| | ErbB Receptors | 2 | 2013 | 603 | 0.070 |
Why?
| | Transcription Factors | 1 | 1996 | 1635 | 0.070 |
Why?
| | Surgical Flaps | 3 | 1986 | 135 | 0.070 |
Why?
| | S Phase | 1 | 2008 | 73 | 0.070 |
Why?
| | Base Sequence | 2 | 2011 | 2137 | 0.070 |
Why?
| | Skull | 2 | 1986 | 129 | 0.070 |
Why?
| | Risk | 2 | 2019 | 853 | 0.070 |
Why?
| | Up-Regulation | 3 | 2019 | 823 | 0.070 |
Why?
| | Computational Biology | 3 | 2019 | 597 | 0.070 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2013 | 758 | 0.070 |
Why?
| | Glucuronidase | 1 | 2007 | 43 | 0.070 |
Why?
| | Australia | 2 | 2023 | 243 | 0.070 |
Why?
| | Sequence Deletion | 1 | 2008 | 178 | 0.070 |
Why?
| | Receptor, Notch2 | 2 | 2020 | 15 | 0.070 |
Why?
| | Li-Fraumeni Syndrome | 1 | 2007 | 13 | 0.070 |
Why?
| | Oligosaccharides | 1 | 2007 | 57 | 0.070 |
Why?
| | 3' Untranslated Regions | 1 | 2008 | 139 | 0.070 |
Why?
| | Cell Movement | 5 | 2015 | 936 | 0.070 |
Why?
| | Factor VIII | 1 | 1987 | 85 | 0.070 |
Why?
| | Adjuvants, Immunologic | 1 | 2008 | 221 | 0.070 |
Why?
| | Receptor, Melanocortin, Type 1 | 1 | 2007 | 7 | 0.070 |
Why?
| | Paraneoplastic Syndromes | 1 | 2007 | 11 | 0.070 |
Why?
| | Cell Self Renewal | 2 | 2017 | 53 | 0.070 |
Why?
| | Chromosome Mapping | 1 | 2008 | 504 | 0.070 |
Why?
| | Vaccinia virus | 2 | 1998 | 42 | 0.070 |
Why?
| | Disease Progression | 2 | 2013 | 2604 | 0.070 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2010 | 508 | 0.070 |
Why?
| | Education, Medical | 1 | 1990 | 244 | 0.070 |
Why?
| | Health Education | 1 | 1990 | 332 | 0.070 |
Why?
| | Myelodysplastic Syndromes | 1 | 1988 | 129 | 0.070 |
Why?
| | Quinazolines | 1 | 2008 | 243 | 0.070 |
Why?
| | Neoadjuvant Therapy | 2 | 2006 | 382 | 0.060 |
Why?
| | Models, Biological | 4 | 2019 | 1698 | 0.060 |
Why?
| | Binding Sites | 2 | 2008 | 1244 | 0.060 |
Why?
| | Magnetic Resonance Imaging | 1 | 2018 | 3387 | 0.060 |
Why?
| | Enterobacteriaceae | 1 | 2006 | 39 | 0.060 |
Why?
| | Colony Count, Microbial | 1 | 2006 | 116 | 0.060 |
Why?
| | Hemophilia A | 1 | 1987 | 115 | 0.060 |
Why?
| | Spinal Cord Compression | 1 | 1985 | 17 | 0.060 |
Why?
| | Hypercalcemia | 1 | 1985 | 18 | 0.060 |
Why?
| | Vena Cava, Superior | 1 | 1985 | 22 | 0.060 |
Why?
| | Fasciotomy | 1 | 1985 | 13 | 0.060 |
Why?
| | Diphosphonates | 1 | 2006 | 56 | 0.060 |
Why?
| | Viral Vaccines | 2 | 1998 | 94 | 0.060 |
Why?
| | Genome, Human | 1 | 2008 | 392 | 0.060 |
Why?
| | Water Microbiology | 1 | 2006 | 85 | 0.060 |
Why?
| | PTEN Phosphohydrolase | 1 | 2007 | 158 | 0.060 |
Why?
| | DNA-Binding Proteins | 1 | 2013 | 1423 | 0.060 |
Why?
| | Infant | 2 | 2019 | 9001 | 0.060 |
Why?
| | Leukocytes, Mononuclear | 1 | 2008 | 539 | 0.060 |
Why?
| | Forearm Injuries | 1 | 1985 | 8 | 0.060 |
Why?
| | Chromates | 1 | 1985 | 1 | 0.060 |
Why?
| | Retroperitoneal Neoplasms | 1 | 2005 | 24 | 0.060 |
Why?
| | Kidney Transplantation | 1 | 1991 | 603 | 0.060 |
Why?
| | In Vitro Techniques | 5 | 2012 | 1047 | 0.060 |
Why?
| | Chromium | 1 | 1985 | 13 | 0.060 |
Why?
| | Testicular Neoplasms | 2 | 1984 | 104 | 0.060 |
Why?
| | Neoplasm Invasiveness | 3 | 2018 | 478 | 0.060 |
Why?
| | Wrist | 1 | 1985 | 53 | 0.060 |
Why?
| | Forearm | 1 | 1985 | 117 | 0.060 |
Why?
| | Karyotyping | 4 | 1994 | 107 | 0.060 |
Why?
| | Macrophages | 4 | 1988 | 1464 | 0.060 |
Why?
| | Axilla | 1 | 2004 | 45 | 0.060 |
Why?
| | Burns, Chemical | 1 | 1985 | 29 | 0.060 |
Why?
| | Acute Disease | 6 | 1991 | 965 | 0.060 |
Why?
| | Hand Injuries | 1 | 1985 | 36 | 0.060 |
Why?
| | Protein Transport | 2 | 2018 | 421 | 0.060 |
Why?
| | Immunotherapy, Adoptive | 2 | 1998 | 296 | 0.060 |
Why?
| | Skin Transplantation | 1 | 1985 | 84 | 0.060 |
Why?
| | Ki-67 Antigen | 1 | 2004 | 107 | 0.060 |
Why?
| | Immunoenzyme Techniques | 1 | 2004 | 205 | 0.060 |
Why?
| | Blood Cell Count | 5 | 1995 | 52 | 0.060 |
Why?
| | Monocytes | 5 | 1983 | 546 | 0.060 |
Why?
| | Neoplasm Metastasis | 4 | 2007 | 610 | 0.060 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2024 | 9 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2012 | 2064 | 0.060 |
Why?
| | Phosphorylation | 2 | 2018 | 1686 | 0.060 |
Why?
| | Azepines | 1 | 2024 | 88 | 0.050 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2004 | 53 | 0.050 |
Why?
| | Genetic Testing | 1 | 2007 | 428 | 0.050 |
Why?
| | Escherichia coli | 3 | 2006 | 771 | 0.050 |
Why?
| | Urine | 4 | 1973 | 56 | 0.050 |
Why?
| | Age Distribution | 2 | 2018 | 373 | 0.050 |
Why?
| | Monitoring, Immunologic | 1 | 2023 | 23 | 0.050 |
Why?
| | Inhibitory Concentration 50 | 1 | 2003 | 82 | 0.050 |
Why?
| | Receptors, Lysophosphatidic Acid | 1 | 2023 | 30 | 0.050 |
Why?
| | Molecular Sequence Data | 1 | 2008 | 2822 | 0.050 |
Why?
| | Schistosoma | 1 | 1983 | 23 | 0.050 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2003 | 89 | 0.050 |
Why?
| | Carcinoma, Transitional Cell | 1 | 1983 | 60 | 0.050 |
Why?
| | Neutropenia | 3 | 1980 | 134 | 0.050 |
Why?
| | Multiple Sclerosis | 1 | 2008 | 435 | 0.050 |
Why?
| | Protein Kinase Inhibitors | 2 | 2019 | 880 | 0.050 |
Why?
| | Triazoles | 1 | 2024 | 151 | 0.050 |
Why?
| | CTLA-4 Antigen | 1 | 2023 | 87 | 0.050 |
Why?
| | Smoking | 1 | 1990 | 1459 | 0.050 |
Why?
| | Immunity, Cellular | 1 | 1984 | 263 | 0.050 |
Why?
| | Receptors, Melanocortin | 1 | 2002 | 1 | 0.050 |
Why?
| | Receptors, Corticotropin | 1 | 2002 | 3 | 0.050 |
Why?
| | Vitamin A | 1 | 1982 | 55 | 0.050 |
Why?
| | Genes, cdc | 1 | 2002 | 11 | 0.050 |
Why?
| | Cell Lineage | 1 | 2024 | 336 | 0.050 |
Why?
| | Wnt Signaling Pathway | 1 | 2024 | 166 | 0.050 |
Why?
| | Uveal Neoplasms | 1 | 2021 | 10 | 0.050 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2002 | 43 | 0.050 |
Why?
| | Clinical Trials as Topic | 4 | 2018 | 1003 | 0.050 |
Why?
| | Diskectomy | 1 | 2021 | 21 | 0.050 |
Why?
| | Neck Pain | 1 | 2021 | 26 | 0.050 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2021 | 50 | 0.050 |
Why?
| | Leukocytosis | 4 | 1974 | 32 | 0.050 |
Why?
| | Incidence | 3 | 2009 | 2638 | 0.050 |
Why?
| | Young Adult | 4 | 2020 | 12349 | 0.050 |
Why?
| | Disease Models, Animal | 3 | 2018 | 3947 | 0.050 |
Why?
| | Antigens | 2 | 1983 | 353 | 0.050 |
Why?
| | Gene Expression | 3 | 2008 | 1455 | 0.050 |
Why?
| | Isotretinoin | 2 | 1994 | 23 | 0.050 |
Why?
| | PAX3 Transcription Factor | 2 | 2015 | 11 | 0.050 |
Why?
| | Paired Box Transcription Factors | 2 | 2015 | 40 | 0.050 |
Why?
| | Bone Neoplasms | 1 | 1983 | 231 | 0.050 |
Why?
| | Postoperative Period | 1 | 2022 | 323 | 0.040 |
Why?
| | Cyclin-Dependent Kinases | 1 | 2002 | 130 | 0.040 |
Why?
| | Smallpox Vaccine | 2 | 1998 | 23 | 0.040 |
Why?
| | Administration, Oral | 5 | 1995 | 767 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2003 | 503 | 0.040 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p15 | 2 | 2000 | 16 | 0.040 |
Why?
| | Leukemia, Lymphoid | 6 | 1979 | 27 | 0.040 |
Why?
| | Enterobacter cloacae | 1 | 2020 | 4 | 0.040 |
Why?
| | Eosinophils | 1 | 1983 | 323 | 0.040 |
Why?
| | Mycobacterium chelonae | 1 | 2020 | 8 | 0.040 |
Why?
| | Leukemia, Myeloid, Acute | 4 | 1984 | 592 | 0.040 |
Why?
| | Quality of Life | 2 | 2022 | 2688 | 0.040 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 2020 | 47 | 0.040 |
Why?
| | Tetracycline | 1 | 2000 | 12 | 0.040 |
Why?
| | Oxidoreductases | 1 | 2020 | 89 | 0.040 |
Why?
| | Gene Amplification | 1 | 2020 | 104 | 0.040 |
Why?
| | Age Factors | 4 | 2019 | 3122 | 0.040 |
Why?
| | Tocopherols | 2 | 1994 | 23 | 0.040 |
Why?
| | RNA, Messenger | 3 | 2019 | 2679 | 0.040 |
Why?
| | Chromosomes, Human, 6-12 and X | 2 | 1994 | 5 | 0.040 |
Why?
| | Gene Dosage | 1 | 2020 | 142 | 0.040 |
Why?
| | rho GTP-Binding Proteins | 1 | 2020 | 61 | 0.040 |
Why?
| | Endotoxins | 2 | 1978 | 215 | 0.040 |
Why?
| | Whole Genome Sequencing | 1 | 2020 | 130 | 0.040 |
Why?
| | Data Curation | 1 | 2019 | 11 | 0.040 |
Why?
| | Germ-Free Life | 1 | 1979 | 33 | 0.040 |
Why?
| | Enzyme Inhibitors | 1 | 2003 | 813 | 0.040 |
Why?
| | Joint Prosthesis | 1 | 2019 | 18 | 0.040 |
Why?
| | Vincristine | 3 | 1984 | 109 | 0.040 |
Why?
| | Carotenoids | 2 | 1994 | 38 | 0.040 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2008 | 1046 | 0.040 |
Why?
| | Cyclophosphamide | 3 | 1983 | 228 | 0.040 |
Why?
| | Aneuploidy | 2 | 1994 | 92 | 0.040 |
Why?
| | Finger Injuries | 1 | 2019 | 24 | 0.040 |
Why?
| | Dysplastic Nevus Syndrome | 1 | 1998 | 2 | 0.040 |
Why?
| | Injections, Subcutaneous | 5 | 2007 | 147 | 0.040 |
Why?
| | Mast Cells | 1 | 2020 | 141 | 0.040 |
Why?
| | Pyrimidinones | 1 | 2019 | 103 | 0.040 |
Why?
| | Erythropoietin | 3 | 1982 | 84 | 0.040 |
Why?
| | Azetidines | 1 | 2018 | 40 | 0.040 |
Why?
| | Dynamins | 1 | 2018 | 34 | 0.040 |
Why?
| | Oncostatin M | 1 | 1998 | 6 | 0.040 |
Why?
| | Prosthesis Failure | 1 | 2019 | 114 | 0.040 |
Why?
| | Arthritis | 1 | 2019 | 90 | 0.040 |
Why?
| | Echocardiography, Transesophageal | 1 | 1999 | 91 | 0.040 |
Why?
| | Heterografts | 1 | 2018 | 129 | 0.040 |
Why?
| | Chromosome Deletion | 2 | 1994 | 102 | 0.040 |
Why?
| | Membrane Glycoproteins | 1 | 2020 | 468 | 0.040 |
Why?
| | Levamisole | 1 | 1977 | 19 | 0.040 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2018 | 181 | 0.040 |
Why?
| | Bone Density Conservation Agents | 1 | 2018 | 71 | 0.040 |
Why?
| | Bcl-2-Like Protein 11 | 1 | 2017 | 38 | 0.040 |
Why?
| | Genetic Association Studies | 1 | 2019 | 361 | 0.040 |
Why?
| | Drug Approval | 1 | 2018 | 86 | 0.040 |
Why?
| | Drug Utilization | 1 | 2018 | 169 | 0.030 |
Why?
| | Sex Distribution | 1 | 2018 | 358 | 0.030 |
Why?
| | Skilled Nursing Facilities | 1 | 2018 | 131 | 0.030 |
Why?
| | Precancerous Conditions | 1 | 1998 | 162 | 0.030 |
Why?
| | Drug Evaluation | 4 | 1991 | 80 | 0.030 |
Why?
| | Consensus | 1 | 2020 | 610 | 0.030 |
Why?
| | Felty Syndrome | 4 | 1980 | 4 | 0.030 |
Why?
| | Gene Knockout Techniques | 1 | 2017 | 108 | 0.030 |
Why?
| | Range of Motion, Articular | 1 | 2019 | 365 | 0.030 |
Why?
| | Anesthesia | 1 | 2018 | 129 | 0.030 |
Why?
| | Genes, p53 | 1 | 1997 | 70 | 0.030 |
Why?
| | Thioguanine | 2 | 1984 | 18 | 0.030 |
Why?
| | Pharmacogenetics | 1 | 2018 | 172 | 0.030 |
Why?
| | Menopause | 2 | 2006 | 291 | 0.030 |
Why?
| | Carmustine | 3 | 1986 | 50 | 0.030 |
Why?
| | CD146 Antigen | 1 | 2016 | 41 | 0.030 |
Why?
| | MCF-7 Cells | 1 | 2016 | 115 | 0.030 |
Why?
| | Cytarabine | 2 | 1984 | 57 | 0.030 |
Why?
| | Cicatrix | 1 | 1997 | 59 | 0.030 |
Why?
| | Thrombocytopenia | 4 | 2007 | 185 | 0.030 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2016 | 80 | 0.030 |
Why?
| | Splenomegaly | 2 | 1995 | 15 | 0.030 |
Why?
| | Hodgkin Disease | 4 | 1985 | 134 | 0.030 |
Why?
| | Vinblastine | 2 | 2006 | 68 | 0.030 |
Why?
| | Combined Modality Therapy | 3 | 1998 | 1201 | 0.030 |
Why?
| | Cancer Vaccines | 1 | 1997 | 163 | 0.030 |
Why?
| | Prostatic Neoplasms | 1 | 2003 | 1016 | 0.030 |
Why?
| | Interleukin-2 | 3 | 2006 | 434 | 0.030 |
Why?
| | Drug Administration Schedule | 4 | 2007 | 764 | 0.030 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2016 | 158 | 0.030 |
Why?
| | Mercaptopurine | 2 | 1972 | 15 | 0.030 |
Why?
| | Lymphatic Diseases | 1 | 1995 | 21 | 0.030 |
Why?
| | Gene Deletion | 1 | 1997 | 370 | 0.030 |
Why?
| | Veins | 1 | 1995 | 59 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2016 | 169 | 0.030 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2015 | 62 | 0.030 |
Why?
| | Primary Myelofibrosis | 1 | 1974 | 9 | 0.030 |
Why?
| | Polycythemia Vera | 1 | 1974 | 12 | 0.030 |
Why?
| | Infusions, Intravenous | 2 | 1995 | 394 | 0.030 |
Why?
| | Protein Binding | 2 | 2018 | 2110 | 0.030 |
Why?
| | Surgeons | 1 | 2018 | 259 | 0.030 |
Why?
| | Retinoids | 1 | 2014 | 33 | 0.030 |
Why?
| | Genetic Linkage | 1 | 2015 | 299 | 0.030 |
Why?
| | Inpatients | 1 | 2018 | 468 | 0.030 |
Why?
| | Random Allocation | 3 | 1990 | 344 | 0.030 |
Why?
| | Culture Techniques | 4 | 1979 | 80 | 0.030 |
Why?
| | Proteinuria | 1 | 1974 | 88 | 0.030 |
Why?
| | Chromosomes, Human, 16-18 | 1 | 1994 | 4 | 0.030 |
Why?
| | Chromosomes, Human, Pair 13 | 1 | 1994 | 14 | 0.030 |
Why?
| | beta Carotene | 1 | 1994 | 21 | 0.030 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 1994 | 29 | 0.030 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 1994 | 48 | 0.030 |
Why?
| | Vaginal Neoplasms | 1 | 1993 | 12 | 0.030 |
Why?
| | Vulvar Neoplasms | 1 | 1993 | 11 | 0.030 |
Why?
| | Vitamin B 12 | 1 | 1974 | 122 | 0.030 |
Why?
| | Estrogens | 1 | 2016 | 342 | 0.030 |
Why?
| | Catheterization, Central Venous | 1 | 1995 | 103 | 0.030 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 1994 | 43 | 0.030 |
Why?
| | Pilot Projects | 1 | 2018 | 1568 | 0.030 |
Why?
| | Translocation, Genetic | 1 | 1994 | 97 | 0.030 |
Why?
| | Anus Neoplasms | 1 | 1993 | 30 | 0.030 |
Why?
| | Specimen Handling | 1 | 2014 | 163 | 0.030 |
Why?
| | In Situ Hybridization | 1 | 1994 | 291 | 0.030 |
Why?
| | Administration, Intranasal | 3 | 1989 | 83 | 0.030 |
Why?
| | Gonanes | 1 | 2013 | 27 | 0.030 |
Why?
| | Feedback, Physiological | 1 | 2013 | 76 | 0.030 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 1994 | 195 | 0.030 |
Why?
| | Ascorbic Acid | 1 | 1994 | 119 | 0.030 |
Why?
| | Alphapapillomavirus | 1 | 2013 | 40 | 0.030 |
Why?
| | Receptor, Notch1 | 1 | 2013 | 61 | 0.030 |
Why?
| | Anemia, Aplastic | 3 | 1983 | 36 | 0.030 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2012 | 27 | 0.030 |
Why?
| | Retinal Dehydrogenase | 1 | 2012 | 30 | 0.030 |
Why?
| | Cetuximab | 1 | 2013 | 93 | 0.030 |
Why?
| | Iron | 3 | 1989 | 282 | 0.030 |
Why?
| | Phenytoin | 2 | 1962 | 17 | 0.020 |
Why?
| | Mechlorethamine | 3 | 1982 | 63 | 0.020 |
Why?
| | Tumor Microenvironment | 1 | 2016 | 624 | 0.020 |
Why?
| | Individuality | 1 | 1994 | 156 | 0.020 |
Why?
| | Rectal Neoplasms | 1 | 1993 | 136 | 0.020 |
Why?
| | Pathology, Clinical | 1 | 2012 | 36 | 0.020 |
Why?
| | Epithelial Cells | 1 | 1998 | 1043 | 0.020 |
Why?
| | Flow Cytometry | 3 | 2008 | 1142 | 0.020 |
Why?
| | Benzoates | 1 | 1972 | 41 | 0.020 |
Why?
| | Patient Discharge | 1 | 2018 | 854 | 0.020 |
Why?
| | Response Elements | 1 | 2012 | 89 | 0.020 |
Why?
| | Vaccines | 1 | 1997 | 396 | 0.020 |
Why?
| | Precision Medicine | 1 | 2016 | 386 | 0.020 |
Why?
| | Coloring Agents | 1 | 2012 | 75 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2012 | 257 | 0.020 |
Why?
| | Hawaii | 1 | 1991 | 32 | 0.020 |
Why?
| | Mice, SCID | 1 | 2012 | 350 | 0.020 |
Why?
| | Isoenzymes | 1 | 2012 | 302 | 0.020 |
Why?
| | Gene Silencing | 1 | 2012 | 183 | 0.020 |
Why?
| | Mitosis | 1 | 1992 | 178 | 0.020 |
Why?
| | Mice, Inbred C57BL | 4 | 2010 | 5281 | 0.020 |
Why?
| | Sodium | 2 | 1962 | 202 | 0.020 |
Why?
| | Prednisone | 1 | 1972 | 230 | 0.020 |
Why?
| | DNA Repair | 1 | 2013 | 206 | 0.020 |
Why?
| | Melphalan | 3 | 1986 | 29 | 0.020 |
Why?
| | Bacteria | 1 | 1977 | 817 | 0.020 |
Why?
| | 9,10-Dimethyl-1,2-benzanthracene | 1 | 2010 | 24 | 0.020 |
Why?
| | Interleukin-8 | 1 | 2012 | 262 | 0.020 |
Why?
| | Paclitaxel | 1 | 2012 | 214 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2013 | 357 | 0.020 |
Why?
| | Hepatectomy | 2 | 1962 | 210 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2012 | 586 | 0.020 |
Why?
| | Dermatology | 1 | 2012 | 117 | 0.020 |
Why?
| | Sex Ratio | 1 | 1990 | 13 | 0.020 |
Why?
| | Pigmentation | 1 | 2010 | 51 | 0.020 |
Why?
| | Megakaryocytes | 2 | 1981 | 31 | 0.020 |
Why?
| | DNA Damage | 1 | 2013 | 370 | 0.020 |
Why?
| | Staining and Labeling | 1 | 2010 | 137 | 0.020 |
Why?
| | Blotting, Western | 1 | 2013 | 1170 | 0.020 |
Why?
| | Circadian Rhythm | 1 | 1994 | 412 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2012 | 573 | 0.020 |
Why?
| | California | 1 | 1991 | 398 | 0.020 |
Why?
| | DNA Primers | 1 | 2011 | 510 | 0.020 |
Why?
| | Penicillin V | 1 | 1989 | 3 | 0.020 |
Why?
| | Imidazoles | 1 | 2010 | 229 | 0.020 |
Why?
| | Body Surface Area | 1 | 2009 | 33 | 0.020 |
Why?
| | Deferoxamine | 1 | 1989 | 18 | 0.020 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2010 | 153 | 0.020 |
Why?
| | Diagnosis, Differential | 2 | 2012 | 1412 | 0.020 |
Why?
| | Lithium Chloride | 2 | 1986 | 11 | 0.020 |
Why?
| | Radionuclide Imaging | 1 | 1989 | 122 | 0.020 |
Why?
| | Mouth | 1 | 1989 | 80 | 0.020 |
Why?
| | Bone Regeneration | 2 | 1986 | 23 | 0.020 |
Why?
| | Cellular Senescence | 1 | 2010 | 176 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2011 | 757 | 0.020 |
Why?
| | Interferon beta-1a | 1 | 2008 | 12 | 0.020 |
Why?
| | Glatiramer Acetate | 1 | 2008 | 18 | 0.020 |
Why?
| | Abdomen | 1 | 2009 | 118 | 0.020 |
Why?
| | Anemia | 2 | 1982 | 160 | 0.020 |
Why?
| | Colorado | 2 | 2009 | 4399 | 0.020 |
Why?
| | Eye Color | 1 | 1988 | 3 | 0.020 |
Why?
| | Temperature | 3 | 1981 | 632 | 0.020 |
Why?
| | Upper Extremity | 1 | 2009 | 92 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2009 | 512 | 0.020 |
Why?
| | Interferon-beta | 1 | 2008 | 88 | 0.020 |
Why?
| | Cimetidine | 1 | 1988 | 13 | 0.020 |
Why?
| | Surgical Procedures, Operative | 1 | 1971 | 243 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2008 | 150 | 0.020 |
Why?
| | Chlorides | 2 | 1986 | 137 | 0.020 |
Why?
| | Contusions | 1 | 2007 | 20 | 0.020 |
Why?
| | Nausea | 1 | 2007 | 108 | 0.020 |
Why?
| | Alanine Transaminase | 1 | 2007 | 151 | 0.020 |
Why?
| | Leukopenia | 2 | 1991 | 28 | 0.020 |
Why?
| | Liver Neoplasms | 2 | 2006 | 637 | 0.020 |
Why?
| | Neoplasms, Unknown Primary | 1 | 2006 | 13 | 0.020 |
Why?
| | Molecular Weight | 2 | 1979 | 331 | 0.020 |
Why?
| | Enterobacter aerogenes | 1 | 2006 | 3 | 0.020 |
Why?
| | Laparotomy | 1 | 2007 | 106 | 0.020 |
Why?
| | Vaccines, Combined | 2 | 1997 | 48 | 0.020 |
Why?
| | Electric Injuries | 1 | 1986 | 2 | 0.020 |
Why?
| | Hydroxyurea | 2 | 1984 | 33 | 0.020 |
Why?
| | N-Acetylgalactosaminyltransferases | 1 | 2005 | 6 | 0.020 |
Why?
| | Prospective Studies | 4 | 2005 | 7069 | 0.020 |
Why?
| | MART-1 Antigen | 1 | 2005 | 12 | 0.020 |
Why?
| | Hemoglobins | 1 | 1988 | 337 | 0.020 |
Why?
| | Tomography, Emission-Computed | 1 | 1986 | 66 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 820 | 0.020 |
Why?
| | Double-Blind Method | 3 | 1998 | 1856 | 0.020 |
Why?
| | Metaproterenol | 1 | 1985 | 2 | 0.020 |
Why?
| | Reference Standards | 1 | 2006 | 170 | 0.020 |
Why?
| | Culture Media | 4 | 1977 | 164 | 0.020 |
Why?
| | Antigens, CD | 1 | 2008 | 482 | 0.020 |
Why?
| | Extremities | 1 | 2006 | 128 | 0.020 |
Why?
| | Lower Extremity | 1 | 2009 | 402 | 0.020 |
Why?
| | Fatigue | 1 | 2007 | 316 | 0.020 |
Why?
| | Neoplasm Proteins | 2 | 2005 | 420 | 0.020 |
Why?
| | Platelet Count | 2 | 1986 | 82 | 0.010 |
Why?
| | Erythrocytes | 3 | 1981 | 673 | 0.010 |
Why?
| | Disease Outbreaks | 1 | 1988 | 347 | 0.010 |
Why?
| | Kaplan-Meier Estimate | 1 | 2007 | 856 | 0.010 |
Why?
| | Edetic Acid | 1 | 1985 | 46 | 0.010 |
Why?
| | Wrist Injuries | 1 | 1985 | 27 | 0.010 |
Why?
| | Accidents, Occupational | 1 | 1985 | 13 | 0.010 |
Why?
| | Blood Platelets | 3 | 1974 | 377 | 0.010 |
Why?
| | Dendritic Cells | 1 | 2008 | 477 | 0.010 |
Why?
| | Spleen | 2 | 1981 | 509 | 0.010 |
Why?
| | Constriction, Pathologic | 1 | 1985 | 228 | 0.010 |
Why?
| | Epinephrine | 1 | 1985 | 140 | 0.010 |
Why?
| | Survivors | 1 | 2008 | 462 | 0.010 |
Why?
| | Nucleoproteins | 1 | 1984 | 28 | 0.010 |
Why?
| | Syndrome | 1 | 1985 | 336 | 0.010 |
Why?
| | Emergencies | 1 | 1985 | 154 | 0.010 |
Why?
| | Remission Induction | 2 | 1995 | 268 | 0.010 |
Why?
| | Necrosis | 1 | 1985 | 229 | 0.010 |
Why?
| | Administration, Topical | 1 | 1984 | 144 | 0.010 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2005 | 381 | 0.010 |
Why?
| | Podophyllotoxin | 1 | 1984 | 7 | 0.010 |
Why?
| | Sex Characteristics | 1 | 2009 | 722 | 0.010 |
Why?
| | Pregnancy Trimester, Third | 1 | 2004 | 108 | 0.010 |
Why?
| | Neuropilin-1 | 1 | 2003 | 8 | 0.010 |
Why?
| | Heart Arrest | 2 | 1984 | 307 | 0.010 |
Why?
| | Liver | 2 | 1962 | 1827 | 0.010 |
Why?
| | Etoposide | 1 | 1984 | 148 | 0.010 |
Why?
| | Blood Vessels | 1 | 1985 | 183 | 0.010 |
Why?
| | Fibula | 1 | 1983 | 46 | 0.010 |
Why?
| | Cell Nucleolus | 1 | 1983 | 17 | 0.010 |
Why?
| | Enterobacter | 1 | 1983 | 7 | 0.010 |
Why?
| | Antibodies, Antinuclear | 1 | 1983 | 66 | 0.010 |
Why?
| | Busulfan | 1 | 1982 | 15 | 0.010 |
Why?
| | Cell Nucleus | 2 | 1984 | 580 | 0.010 |
Why?
| | Klebsiella pneumoniae | 1 | 1983 | 44 | 0.010 |
Why?
| | Absorption | 1 | 1982 | 57 | 0.010 |
Why?
| | Ultrasonography | 1 | 2006 | 712 | 0.010 |
Why?
| | Sodium, Dietary | 1 | 1962 | 37 | 0.010 |
Why?
| | Erythropoiesis | 1 | 1982 | 51 | 0.010 |
Why?
| | Bleomycin | 1 | 1984 | 241 | 0.010 |
Why?
| | Cytoplasm | 1 | 1983 | 258 | 0.010 |
Why?
| | Ischemia | 1 | 1985 | 394 | 0.010 |
Why?
| | Hypoglycemia | 1 | 2007 | 425 | 0.010 |
Why?
| | Carcinoma, Small Cell | 1 | 1982 | 168 | 0.010 |
Why?
| | Schistosomiasis | 1 | 1982 | 38 | 0.010 |
Why?
| | Transplantation, Autologous | 4 | 1984 | 211 | 0.010 |
Why?
| | Pain | 1 | 2007 | 751 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2009 | 3021 | 0.010 |
Why?
| | Glucose | 1 | 2007 | 983 | 0.010 |
Why?
| | Glycogen Storage Disease Type I | 1 | 1980 | 5 | 0.010 |
Why?
| | Choriocarcinoma | 1 | 1981 | 9 | 0.010 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2001 | 210 | 0.010 |
Why?
| | Biopsy | 1 | 2004 | 1079 | 0.010 |
Why?
| | Thymidine Kinase | 1 | 2000 | 15 | 0.010 |
Why?
| | Regeneration | 1 | 1962 | 176 | 0.010 |
Why?
| | Blood Transfusion | 2 | 1974 | 295 | 0.010 |
Why?
| | Pseudomonas aeruginosa | 1 | 1983 | 344 | 0.010 |
Why?
| | Pregnancy | 2 | 2004 | 6373 | 0.010 |
Why?
| | Retinoblastoma Protein | 1 | 2000 | 54 | 0.010 |
Why?
| | Antibodies, Bacterial | 1 | 1980 | 137 | 0.010 |
Why?
| | Doxycycline | 1 | 2000 | 57 | 0.010 |
Why?
| | Luciferases | 1 | 2000 | 147 | 0.010 |
Why?
| | Chromosomes, Human, 4-5 | 1 | 1979 | 1 | 0.010 |
Why?
| | Anemia, Macrocytic | 1 | 1979 | 4 | 0.010 |
Why?
| | Simplexvirus | 1 | 2000 | 80 | 0.010 |
Why?
| | Thrombocytosis | 1 | 1979 | 6 | 0.010 |
Why?
| | Electrophoresis, Cellulose Acetate | 1 | 1979 | 1 | 0.010 |
Why?
| | Pronase | 1 | 1979 | 5 | 0.010 |
Why?
| | Deoxyribonucleases | 1 | 1979 | 23 | 0.010 |
Why?
| | Herpesvirus 4, Human | 1 | 2000 | 152 | 0.010 |
Why?
| | Ribonucleases | 1 | 1979 | 54 | 0.010 |
Why?
| | Sepsis | 1 | 1985 | 569 | 0.010 |
Why?
| | Plasmids | 1 | 2000 | 355 | 0.010 |
Why?
| | Trypsin | 1 | 1979 | 74 | 0.010 |
Why?
| | Fluorescent Antibody Technique | 3 | 1984 | 370 | 0.010 |
Why?
| | Remission, Spontaneous | 2 | 1977 | 37 | 0.010 |
Why?
| | Autoantibodies | 2 | 1984 | 1464 | 0.010 |
Why?
| | Glucosephosphate Dehydrogenase | 1 | 1979 | 55 | 0.010 |
Why?
| | Hematocrit | 2 | 1977 | 93 | 0.010 |
Why?
| | Bacterial Physiological Phenomena | 1 | 1978 | 58 | 0.010 |
Why?
| | Hypocalcemia | 3 | 1984 | 28 | 0.010 |
Why?
| | Anemia, Hypochromic | 1 | 1977 | 4 | 0.010 |
Why?
| | Nitrogen | 1 | 1979 | 168 | 0.010 |
Why?
| | Transfection | 1 | 2000 | 896 | 0.010 |
Why?
| | Species Specificity | 1 | 1979 | 569 | 0.010 |
Why?
| | Staphylococcus | 1 | 1977 | 74 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1979 | 541 | 0.010 |
Why?
| | Agar | 1 | 1977 | 11 | 0.010 |
Why?
| | Trans-Activators | 1 | 2000 | 384 | 0.010 |
Why?
| | Recombinant Fusion Proteins | 1 | 2000 | 636 | 0.010 |
Why?
| | Pneumonia | 1 | 1983 | 601 | 0.010 |
Why?
| | Arthritis, Rheumatoid | 2 | 1983 | 1088 | 0.010 |
Why?
| | Pericardium | 1 | 1976 | 54 | 0.010 |
Why?
| | Streptococcus pneumoniae | 1 | 1977 | 159 | 0.010 |
Why?
| | Groin | 1 | 1995 | 10 | 0.010 |
Why?
| | Phagocytosis | 1 | 1977 | 361 | 0.010 |
Why?
| | Subclavian Vein | 1 | 1995 | 15 | 0.010 |
Why?
| | Blood Protein Electrophoresis | 1 | 1975 | 8 | 0.010 |
Why?
| | Typhoid-Paratyphoid Vaccines | 1 | 1975 | 4 | 0.010 |
Why?
| | Patient Compliance | 2 | 1989 | 560 | 0.010 |
Why?
| | Pyrogens | 1 | 1975 | 55 | 0.010 |
Why?
| | Iron Radioisotopes | 1 | 1974 | 4 | 0.010 |
Why?
| | Cobalt Radioisotopes | 1 | 1974 | 7 | 0.010 |
Why?
| | Dialysis | 1 | 1974 | 18 | 0.010 |
Why?
| | Pyelonephritis | 1 | 1974 | 10 | 0.010 |
Why?
| | Hospitals, University | 1 | 1995 | 176 | 0.010 |
Why?
| | Centrifugation | 1 | 1974 | 29 | 0.010 |
Why?
| | Child, Preschool | 3 | 1985 | 10487 | 0.010 |
Why?
| | Salmonella | 1 | 1975 | 59 | 0.010 |
Why?
| | Vaccines, Attenuated | 1 | 1995 | 125 | 0.010 |
Why?
| | Skin Physiological Phenomena | 1 | 1994 | 24 | 0.010 |
Why?
| | Photoperiod | 1 | 1994 | 46 | 0.010 |
Why?
| | Drug Costs | 1 | 1994 | 100 | 0.010 |
Why?
| | Adrenal Gland Neoplasms | 1 | 1974 | 84 | 0.010 |
Why?
| | Virus Diseases | 1 | 1976 | 210 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 1981 | 1923 | 0.010 |
Why?
| | Multiple Myeloma | 1 | 1974 | 125 | 0.010 |
Why?
| | Procarbazine | 1 | 1972 | 8 | 0.010 |
Why?
| | Hydrocortisone | 1 | 1975 | 304 | 0.010 |
Why?
| | Diseases in Twins | 1 | 1973 | 176 | 0.010 |
Why?
| | Asthma | 1 | 1985 | 2213 | 0.010 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 1972 | 76 | 0.010 |
Why?
| | Doxorubicin | 2 | 1984 | 324 | 0.010 |
Why?
| | Drug Combinations | 1 | 1972 | 324 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2000 | 2516 | 0.010 |
Why?
| | Length of Stay | 1 | 1995 | 1119 | 0.010 |
Why?
| | Taurodeoxycholic Acid | 1 | 1989 | 1 | 0.010 |
Why?
| | Perfusion | 1 | 1970 | 188 | 0.010 |
Why?
| | Arm | 2 | 1985 | 107 | 0.010 |
Why?
| | Ferritins | 1 | 1989 | 58 | 0.000 |
Why?
| | Debridement | 1 | 1989 | 82 | 0.000 |
Why?
| | Placebos | 1 | 1989 | 201 | 0.000 |
Why?
| | Mouth Mucosa | 1 | 1989 | 89 | 0.000 |
Why?
| | Skin | 1 | 1994 | 717 | 0.000 |
Why?
| | Antibody Formation | 1 | 1970 | 290 | 0.000 |
Why?
| | Bone Marrow Examination | 2 | 1979 | 6 | 0.000 |
Why?
| | Wounds and Injuries | 1 | 1995 | 707 | 0.000 |
Why?
| | Scalp | 1 | 1986 | 34 | 0.000 |
Why?
| | Peak Expiratory Flow Rate | 1 | 1985 | 36 | 0.000 |
Why?
| | Prostaglandins E | 1 | 1985 | 47 | 0.000 |
Why?
| | Saudi Arabia | 1 | 1985 | 6 | 0.000 |
Why?
| | Lactoferrin | 1 | 1985 | 28 | 0.000 |
Why?
| | Immunodiffusion | 1 | 1984 | 15 | 0.000 |
Why?
| | Polysaccharides, Bacterial | 1 | 1985 | 67 | 0.000 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 1984 | 51 | 0.000 |
Why?
| | Angiography | 1 | 1985 | 192 | 0.000 |
Why?
| | Antigen-Antibody Complex | 1 | 1984 | 84 | 0.000 |
Why?
| | Aerosols | 1 | 1985 | 168 | 0.000 |
Why?
| | Teniposide | 1 | 1984 | 3 | 0.000 |
Why?
| | Chromosomes, Human, 21-22 and Y | 1 | 1984 | 4 | 0.000 |
Why?
| | Tissue Preservation | 1 | 1984 | 11 | 0.000 |
Why?
| | Postoperative Complications | 1 | 1995 | 2462 | 0.000 |
Why?
| | Daunorubicin | 1 | 1984 | 25 | 0.000 |
Why?
| | Melanoma-Specific Antigens | 1 | 1983 | 5 | 0.000 |
Why?
| | False Negative Reactions | 1 | 1983 | 51 | 0.000 |
Why?
| | Rats | 2 | 1962 | 5246 | 0.000 |
Why?
| | Syncope | 1 | 1984 | 50 | 0.000 |
Why?
| | Cell Line | 2 | 1983 | 2741 | 0.000 |
Why?
| | Arteries | 1 | 1985 | 261 | 0.000 |
Why?
| | Regional Blood Flow | 1 | 1985 | 458 | 0.000 |
Why?
| | Phosphates | 1 | 1984 | 169 | 0.000 |
Why?
| | Lomustine | 1 | 1982 | 14 | 0.000 |
Why?
| | Heterozygote | 1 | 1983 | 269 | 0.000 |
Why?
| | Egypt | 1 | 1982 | 10 | 0.000 |
Why?
| | Fever | 1 | 1984 | 297 | 0.000 |
Why?
| | Heart Rate | 1 | 1985 | 798 | 0.000 |
Why?
| | Cytotoxicity, Immunologic | 1 | 1981 | 216 | 0.000 |
Why?
| | Mice, Inbred Strains | 1 | 1981 | 402 | 0.000 |
Why?
| | Tachycardia | 1 | 1981 | 56 | 0.000 |
Why?
| | Cell Separation | 1 | 1981 | 312 | 0.000 |
Why?
| | Histocompatibility Antigens Class II | 1 | 1981 | 360 | 0.000 |
Why?
| | Fanconi Anemia | 1 | 1979 | 10 | 0.000 |
Why?
| | Blood Cells | 1 | 1979 | 38 | 0.000 |
Why?
| | Complement System Proteins | 1 | 1981 | 308 | 0.000 |
Why?
| | Blood Pressure | 1 | 1985 | 1712 | 0.000 |
Why?
| | Electrocardiography | 1 | 1981 | 608 | 0.000 |
Why?
| | Cold Temperature | 1 | 1979 | 154 | 0.000 |
Why?
| | Blood | 1 | 1977 | 100 | 0.000 |
Why?
| | Pericardial Effusion | 1 | 1976 | 20 | 0.000 |
Why?
| | Kidney Failure, Chronic | 1 | 1982 | 541 | 0.000 |
Why?
| | Autopsy | 1 | 1976 | 92 | 0.000 |
Why?
| | Cell Count | 1 | 1977 | 310 | 0.000 |
Why?
| | DNA | 1 | 1983 | 1394 | 0.000 |
Why?
| | Alpha-Globulins | 1 | 1975 | 20 | 0.000 |
Why?
| | Recurrence | 1 | 1977 | 1004 | 0.000 |
Why?
| | Cytogenetics | 1 | 1973 | 12 | 0.000 |
Why?
| | Periodicity | 1 | 1973 | 56 | 0.000 |
Why?
| | Muramidase | 1 | 1973 | 77 | 0.000 |
Why?
| | Chronic Disease | 1 | 1977 | 1692 | 0.000 |
Why?
| | Leg | 1 | 1972 | 237 | 0.000 |
Why?
| | Splenectomy | 1 | 1970 | 57 | 0.000 |
Why?
| | Immunity | 1 | 1970 | 139 | 0.000 |
Why?
| | Immunization | 1 | 1970 | 411 | 0.000 |
Why?
| | Swine | 1 | 1970 | 742 | 0.000 |
Why?
| | Sheep | 1 | 1970 | 831 | 0.000 |
Why?
|
|
Robinson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|